Despite encouraging clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from pharmacy benefit managers. These insurers are https://jasonmppj820533.link4blogs.com/62871355/the-medication-faces-is-meeting-managed-care-organization-hurdles-a-look-of-reimbursement-battles